OBJECTIVES:  To assess price trends of hemophilia A and B drugs in the United States in the period January 1, 1992 to October 9, 2016. METHODS:  A list of drugs approved for hemophilia A and B were obtained from the Food and Drug Administration web page from January 1, 1983 to October 9, 2016. Pricing data from January 1, 1992 to October 31, 2016, for the compiled drugs, were extracted from RedBook (Truven Health Analytics). Prices were adjusted for inflation. RESULTS: A total of 9 manufacturers are responsible for the commercialization of 21 proprietary drugs; 15 drugs are indicated for the treatment of hemophilia A and 6 for hemophilia B as of October 9, 2016. For hemophilia A plasma drugs, initial flat price trends upon market entry were observed with an AWP per unit range from $0.75 to $0.92. For hemophilia A recombinant drugs, the initial market AWP hovered below $2.00, until 2013, when 3 new human plasma derived drugs were launched in the US drug market. Over time, these three new drugs alone, increased in price by an average of 54%. On average, recombinant drugs for hemophilia A escalated by 12% over a period of 14 years. Hemophilia B Plasma drugs entered the market in 1992 within an AWP per unit of $0.06 and had an average cumulative price increase of 56% over 14 years. Hemophilia B recombinant drugs also increased over time at an average of 28%. CONCLUSIONS: The prices of hemophilia drugs at market entry increased overtime. Prices of marketed drugs increased faster than inflation. The rising price trend in hemophilia drugs may be largely due to changes in treatment regimens that support prophylactic utilization of hemophilia drugs versus on demand treatment, small number of competitors, R&D cost, and limited drug pricing regulations.